FATE Fate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FATE

Price (delayed)

$4.54

Market cap

$450.54M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$497.03M

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture ...

Highlights
FATE's EPS is up by 44% year-on-year and by 7% since the previous quarter
The net income has grown by 43% YoY and by 7% from the previous quarter
The company's quick ratio has surged by 98% YoY but it fell by 4.2% QoQ
The gross profit has declined by 40% since the previous quarter and by 34% year-on-year
FATE's revenue is down by 40% since the previous quarter and by 34% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fatetherapeutics.com
Peers: SRPT PTCT BDX RNA

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
99.24M
Market cap
$450.54M
Enterprise value
$497.03M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.22
Price to sales (P/S)
7.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.82
Earnings
Revenue
$63.53M
EBIT
-$160.93M
EBITDA
-$142.65M
Free cash flow
-$138.42M
Per share
EPS
-$1.64
Free cash flow per share
-$1.41
Book value per share
$3.74
Revenue per share
$0.65
TBVPS
$5.14
Balance sheet
Total assets
$506.22M
Total liabilities
$137.8M
Debt
$103.54M
Equity
$368.42M
Working capital
$292.45M
Liquidity
Debt to equity
0.28
Current ratio
8.48
Quick ratio
8.5
Net debt/EBITDA
-0.33
Margins
EBITDA margin
-224.5%
Gross margin
100%
Net margin
-253.3%
Operating margin
-299.9%
Efficiency
Return on assets
-28.4%
Return on equity
-38.2%
Return on invested capital
-28.1%
Return on capital employed
-34.5%
Return on sales
-253.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
-5.02%
1 week
-15.61%
1 month
-31.32%
1 year
-27.01%
YTD
21.39%
QTD
-38.15%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$63.53M
Gross profit
$63.53M
Operating income
-$190.51M
Net income
-$160.93M
Gross margin
100%
Net margin
-253.3%
The net margin has dropped by 55% since the previous quarter but it rose by 13% year-on-year
The operating margin has plunged by 54% from the previous quarter but it has grown by 6% YoY
The net income has grown by 43% YoY and by 7% from the previous quarter
The gross profit has declined by 40% since the previous quarter and by 34% year-on-year

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
1.22
P/S
7.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.82
FATE's EPS is up by 44% year-on-year and by 7% since the previous quarter
FATE's price to book (P/B) is 81% lower than its 5-year quarterly average of 6.3 but 36% higher than its last 4 quarters average of 0.9
The company's equity fell by 24% YoY and by 9% QoQ
The stock's price to sales (P/S) is 93% less than its 5-year quarterly average of 100.4 but 80% more than its last 4 quarters average of 3.9
FATE's revenue is down by 40% since the previous quarter and by 34% year-on-year

Efficiency

How efficient is Fate Therapeutics business performance
FATE's return on sales has dropped by 55% since the previous quarter but it is up by 13% year-on-year
The ROIC has grown by 29% YoY and by 2.8% from the previous quarter
The ROE has grown by 25% YoY
Fate Therapeutics's return on assets has increased by 21% YoY

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
The company's quick ratio has surged by 98% YoY but it fell by 4.2% QoQ
FATE's current ratio has soared by 93% YoY but it is down by 3.7% from the previous quarter
The debt is 72% smaller than the equity
The company's equity fell by 24% YoY and by 9% QoQ
The company's debt to equity rose by 22% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.